Abstract

ObjectivesTreatment-resistant schizophrenia is an old term, describing the form of schizophrenia that does not respond to a treatment dose of Chloropromazine, equal to 1,5 gr.Methods20 (n=20) patients have been studied, that were diagnosed with schizophrenia, and did not respond to any combination of typical or non-typical anti-psychotic drugs. These patients were 19-62 years of age, and were administered the BPRS and PANSS scales at start of the examination or the hospitalization, and during the 1st, 3rd, and 6th month evaluation. The said patients were treated with a combination of Amisulpiride, and Clozapine.ResultsThe patients received a dosage range of 400-1200mg for the Amisulpiride, and 300-900mg for the Clozapine. 18 patients (90%) responded to this treatment, and showed an improvement in the BPRS and PANSS scales, from the 1st month of treatment using a combination of Amisulpiride-Clozapine. Later, during the 3rd month of treatment, one of the patients discontinued the treatment, as she presented leucopenia (white cell count: 3250). The discontinuation of Clozapine treatment was decided. Clozapine was replaced by 20mg Olanzapine.ConclusionsDespite the fact that the sample of patients was very small (n=20), it seems that the combination of Amisulpiride and Clozapine is effective for the treatment of patients showing resistance in pharmaceutical treatment and the combination of typical and non-typical neuroleptics.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.